Oral: 25 mg, 75 mg, 150 mg, 300 mg capsules and tablets; 25 mg/ml solution.
Action: Lincosamide antibiotic that binds to the 50S ribosomal subunit, inhibiting peptide bond formation. May be bactericidal or bacteriostatic depending on susceptibility.
Use: Bone and joint infections associated with Gram-positive bacteria, pyoderma, toxoplasmosis and infections associated with the oral cavity. Active against Gram-positive cocci (including penicillin-resistant staphylococci), many obligate anaerobes, mycoplasmas and Toxoplasma gondii. Attains high concentrations in bone and bile. Being a weak base, it becomes ion-trapped (and therefore concentrated) in fluids that are more acidic than plasma, such as prostatic fluid, milk and intracellular fluid. There is complete cross resistance between lincomycin and clindamycin, and partial cross resistance with erythromycin. Use with care in individuals with hepatic or renal impairment.
Safety and handling: Normal precautions should be observed.
Contraindications: Do not use in rabbits, guinea pigs, chinchillas or hamsters.
Adverse reactions: Colitis, vomiting and diarrhoea are reported. Lincosamides cause a potentially fatal clostridial enterotoxaemia in rabbits, guinea pigs, chinchillas and hamsters.
Drug interactions: May enhance the effect of non-depolarizing muscle relaxants (e.g. tubocurarine) and may antagonize the effects of neostigmine and pyridostigmine. Do not administer with macrolide, chloramphenicol or other lincosamide antimicrobials as these combinations are antagonistic.